MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma — Stella

Recruiting

Back to IDH1 wt Allele trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

M D Anderson Cancer Center, Houston, Texas

Key details

Phase

Early testing

Sponsor

M.D. Anderson Cancer Center

Collaborators

DNAtrix, Inc.

Enrollment target

~36 participants

Started

February 2019

Primary completion

September 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov